Tilly J L, Johnson A L
Department of Animal Sciences, Rutgers, University, New Brunswick, New Jersey 08903.
Endocrinology. 1988 Sep;123(3):1433-41. doi: 10.1210/endo-123-3-1433.
Recent studies conducted in our laboratory have demonstrated that plasminogen activator (PA) is present in granulosa cells collected from the largest preovulatory follicle in the ovary of the domestic hen, and that its activity can be modulated by a variety of hormones in vitro. The present study was conducted to evaluate the intracellular mechanisms involved in the control of hen granulosa cell PA activity through the use of physiological and pharmacological agents. Treatment of granulosa cells with increasing doses (1, 10, and 50 ng/tube) of ovine LH resulted in a significant reduction of PA activity, which was accompanied by an increase in intracellular levels of cAMP. Furthermore, the effects of LH were potentiated by cotreatment with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (0.1 mM). Exposure of cells to increasing concentrations of the adenylyl cyclase activator forskolin (0.005, 0.01, 0.05, and 0.1 mM) resulted in a significant reduction in PA activity at all doses given. Similarly, the presence of the cAMP analog 8-bromo-cAMP (0.005, 0.01, 0.05, 0.1, 0.5, 1.5, and 10 mM) caused a dose-dependent inhibition of PA activity from 0.005 to 1.0 mM, further suggesting the involvement of cAMP in the inhibitory regulation of hen granulosa cell PA activity. The induction of intracellular calcium mobilization through the use of the calcium ionophore A23187 (0.1, 0.5, 1, and 2 microM) resulted in a dose-dependent suppression of PA activity. By contrast, treatment of granulosa cells with the tumor-promoting phorbol ester phorbol 12-myristate 13-acetate (PMA; 0.5, 5, 10, 25, and 50 micrograms/tube), a compound that activates protein kinase-C, stimulated PA activity in a dose-dependent fashion; a non-tumor-promoting phorbol ester (phorbol 13-monoacetate; 0.5, 10, and 50 ng/tube) was without effect. Coincubation of granulosa cells with a submaximal dose of PMA (5 ng/tube) and low concentrations of A23187 (0.001, 0.005, 0.01, and 0.05 microM) could not significantly enhance the stimulatory effects of PMA on PA activity; however, higher concentrations of the ionophore (0.1, 0.5, and 1.0 microM) completely abolished PMA-stimulated PA activity. The stimulatory effects of PMA could also be eliminated by cotreatment with a protein kinase-C inhibitor (H-7; 100 microM), a mRNA transcription blocker (actinomycin-D; 5 micrograms/tube), or a protein synthesis inhibitor (cycloheximide; 50 micrograms/tube).(ABSTRACT TRUNCATED AT 400 WORDS)
我们实验室最近进行的研究表明,纤溶酶原激活物(PA)存在于从家鸡卵巢中最大的排卵前卵泡收集的颗粒细胞中,并且其活性在体外可被多种激素调节。本研究旨在通过使用生理和药理试剂评估参与控制鸡颗粒细胞PA活性的细胞内机制。用递增剂量(1、10和50 ng/管)的羊促黄体生成素(LH)处理颗粒细胞,导致PA活性显著降低,同时细胞内cAMP水平升高。此外,与磷酸二酯酶抑制剂3-异丁基-1-甲基黄嘌呤(0.1 mM)共同处理可增强LH的作用。将细胞暴露于递增浓度的腺苷酸环化酶激活剂福斯可林(0.005、0.01、0.05和0.1 mM)下,在所有给定剂量下均导致PA活性显著降低。同样,cAMP类似物8-溴-cAMP(0.005、0.01、0.05、0.1、0.5、1.5和10 mM)的存在导致从0.005到1.0 mM的PA活性呈剂量依赖性抑制,进一步表明cAMP参与鸡颗粒细胞PA活性的抑制调节。通过使用钙离子载体A23187(0.1、0.5、1和2 microM)诱导细胞内钙动员,导致PA活性呈剂量依赖性抑制。相比之下,用促肿瘤佛波酯佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA;0.5、5、10、25和50微克/管)处理颗粒细胞,该化合物可激活蛋白激酶-C,以剂量依赖性方式刺激PA活性;非促肿瘤佛波酯(佛波醇13-单乙酸酯;0.5、10和50 ng/管)则无作用。将颗粒细胞与亚最大剂量的PMA(5 ng/管)和低浓度的A23187(0.001、0.005、0.01和0.05 microM)共同孵育,不能显著增强PMA对PA活性的刺激作用;然而,较高浓度的离子载体(0.1、0.5和1.0 microM)完全消除了PMA刺激的PA活性。PMA的刺激作用也可通过与蛋白激酶-C抑制剂(H-7;100 microM)、mRNA转录阻滞剂(放线菌素-D;5微克/管)或蛋白质合成抑制剂(环己酰亚胺;50微克/管)共同处理而消除。(摘要截断于400字)